BRIEF-Redhill Biopharma received $1.8 mln grant from U.S. National Cancer Institute for Yeliva phase II study

* Redhill biopharma announces National Cancer Institute grant supporting Yeliva phase II hepatocellular carcinoma study
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.